Dyadic International, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DYAI Nasdaq 2836 www.dyadic.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyadic International, Inc.

iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation Schedule - Sep 15th, 2026 6:00 am
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026 - Sep 8th, 2026 7:00 am
Q3 Virtual Investor Summit Presentations Now Available On Demand - Aug 31st, 2026 4:15 pm
Dyadic International (DYAI) Q2 2026 Earnings Call Transcript - Aug 19th, 2026 8:30 am
DYAI: Second Quarter Results - Aug 14th, 2026 11:02 am
Dyadic International, Inc. Q2 2026 Earnings Call Summary - Aug 13th, 2026 6:30 am
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement - Aug 13th, 2026 6:00 am
Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ... - Aug 12th, 2026 11:01 pm
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas - Aug 12th, 2026 6:30 am
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement - Aug 4th, 2026 5:25 am
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days - Jul 28th, 2026 6:30 am
Dyadic Announces Continued Listing on the Nasdaq Capital Market - Jul 24th, 2026 5:30 am
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program - Jul 16th, 2026 6:00 am
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential - Jul 7th, 2026 5:25 am
Dyadic Expands IP Protection and Business Development Activities in Japan - Jun 29th, 2026 5:25 am
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets - Jun 22nd, 2026 6:46 am
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption - Jun 15th, 2026 5:25 am